Designing antifilarial drug trials using clinical trial simulators by Walker, M et al.
  
 
RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE 
 
This is a published version of an open access article published in Nature Communications. 
The final authenticated version is available online at: https://doi.org/10.1038/s41467-020-
16442-y  
The full details of the published version of the article are as follows: 
 
TITLE: Designing antifilarial drug trials using clinical trial simulators 
 
AUTHORS: Martin Walker, Jonathan I. D. Hamley, Philip Milton, Frédéric Monnot, Belén Pedrique 
& Maria-Gloria Basáñez 
 
JOURNAL TITLE: Nature Communications 
PUBLICATION DATE: 1 June 2020 
PUBLISHER: Springer Nature 
DOI: 10.1038/s41467-020-16442-y 
ARTICLE
Designing antifilarial drug trials using
clinical trial simulators
Martin Walker 1,2✉, Jonathan I. D. Hamley2,3,5, Philip Milton2,3,5, Frédéric Monnot4, Belén Pedrique4 &
Maria-Gloria Basáñez2,3
Lymphatic filariasis and onchocerciasis are neglected tropical diseases (NTDs) targeted for
elimination by mass (antifilarial) drug administration. These drugs are predominantly active
against the microfilarial progeny of adult worms. New drugs or combinations are needed to
improve patient therapy and to enhance the effectiveness of interventions in persistent
hotspots of transmission. Several therapies and regimens are currently in (pre-)clinical
testing. Clinical trial simulators (CTSs) project patient outcomes to inform the design of
clinical trials but have not been widely applied to NTDs, where their resource-saving payoffs
could be highly beneficial. We demonstrate the utility of CTSs using our individual-based
onchocerciasis transmission model (EPIONCHO-IBM) that projects trial outcomes of a
hypothetical macrofilaricidal drug. We identify key design decisions that influence the power
of clinical trials, including participant eligibility criteria and post-treatment follow-up times for
measuring infection indicators. We discuss how CTSs help to inform target product profiles.
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The global health community aims to eliminate lymphaticfilariasis (LF, elephantiasis) and onchocerciasis (riverblindness) predominantly by mass drug administration
(MDA) of antifilarial medicines1,2. The three cornerstone drugs
to achieve this goal are albendazole either alone3 or in combi-
nation with ivermectin and/or diethylcarbamazine (DEC) for LF4,
and ivermectin alone for onchocerciasis. In 2017, 465.4 million
people received treatment for LF and 142.4 million people
received ivermectin for onchocerciasis5,6. Ivermectin and DEC
have potent activity against the microfilarial progeny (the stage
transmitted to vectors) of adult worms (macrofilariae). For
onchocerciasis, ivermectin also temporarily inhibits the produc-
tion of microfilariae (mf) by adult female Onchocerca volvulus7
and is partially macrofilaricidal after multiple doses8. For LF,
combinations of DEC and albendazole9, and triple combination
therapy, IDA (ivermectin with DEC and albendazole)4, has sig-
nificant activity against adult worms.
The suppression of mf elicited by antifilarial drugs—combined
with their efficacy in single oral doses—makes them perfectly
suited for lowering and potentially interrupting transmission of
filarial infections by MDA if delivered at a high coverage and
treatment adherence, and on either an annual or semi-annual
basis2. For LF, the microfilaricidal (and macrofilaricidal) efficacy
of the drugs, and the shorter life-expectancy of the adult worm
compared to O. volvulus (about 5 years compared to about 10
years), has led to the expectation that widespread elimination is
feasible, particularly if MDA is combined with vector control10,11.
As of 2017, 21 out of 73 LF-endemic countries had stopped MDA
and transitioned to post-treatment surveillance6. For oncho-
cerciasis, MDA has greatly reduced morbidity and excess
mortality12,13 and has successfully eliminated onchocerciasis
transmission from Colombia14, Ecuador15, northern Venezuela16,
Mexico17, and Guatemala in Latin America18. Good progress
towards elimination has also been made in Africa19, which bears
99% of the onchocerciasis cases, with notable successes in foci in
Mali, Senegal20,21 Nigeria19 and Sudan22.
However, the long-lived nature of adult O. volvulus, and the
persistence of focal areas of intense transmission mean that
elimination of onchocerciasis at a country scale will be extremely
challenging within currently proposed timeframes23. Despite
many years of MDA, transmission continues in highly endemic
onchocerciasis communities with high vector biting rates24–27.
Moreover, in areas of Central and West Africa where loiasis
(African eye worm28, caused by another filarial parasite, Loa loa)
occurs co-endemically with onchocerciasis, ivermectin cannot be
safely delivered through routine MDA because of the rare but
severe and life-threatening reactions associated with the killing of
L. loa mf in heavily microfilaraemic individuals29. Additionally,
suboptimal responses to ivermectin (potentially indicating loss of
drug efficacy) have been reported phenotypically in Ghana30 and
confirmed genetically in Ghana and Cameroon31. Hence, there is
a growing consensus that it is unlikely that ivermectin alone will
be sufficient to eliminate onchocerciasis in all endemic African
settings and that drugs with macrofilaricidal properties are
pressingly needed32–34. Macrofilaricides will help accelerate pro-
gress towards country-wide elimination and improve individual
patient treatment options. Public and privately funded drug
development partnerships for the neglected tropical diseases
(NTDs), including onchocerciasis, have been developed in
response to this need35–38.
Clinical trial simulation is the (mathematical) representation of
clinical trials to inform decision-making on trial design by for-
ward projecting likely trial outcomes39, e.g., Vegvari et al.40
Simulation has been widely implemented in the pharmaceutical
sector to assist with the design of trials, often seeking to balance
the cost of collecting data with the information (such as safety
and/or efficacy) on the drug under consideration that these data
will provide41. Clinical trial simulation has not been used to assist
drug development in the NTD domain, although simulation has
been used widely to project the impact of population-level
interventions on onchocerciasis, LF and other NTDs42, and
to inform the design of cluster intervention trials targeting
elimination of soil-transmitted helminthiases43,44. Simulation
could inform the design of clinical trials, offering resource savings
that may be particularly important for NTD drug development.
Simulators can include all aspects of the trial protocol, from the
recruitment of participants meeting pre-defined eligibility criteria
in simulated populations, to the projection of trial outcomes
under desired drug properties defined by a target product profile
(TPP). Simulations can answer questions such as: (a) how many
trial participants need to be recruited to demonstrate superiority
over existing treatments (in two- or multi-armed trials); (b) when
should participants be followed up, and (c) what infection indi-
cators should be measured as primary and secondary outcomes?
These questions are particularly pertinent to the design of anti-
filarial drug trials because: (a) drugs are generally not completely
curative, yet can exert long-lasting reductions in infection
intensities; (b) macrofilaricidal drug responses are typically
quantified indirectly by measuring mf; (c) response variation
among participants is generally very high, and (d) reinfection by
unexposed drug-naïve parasites during trials conducted in
endemic settings is inevitable (and can be accounted for using
trial simulators that explicitly model transmission).
Here we illustrate how a clinical trial simulator (CTS) can be
used to help design antifilarial drug trials, using as an example a
hypothetical macrofilaricidal drug for the treatment of oncho-
cerciasis. We use an adaptation of our individual-based oncho-
cerciasis transmission model, EPIONCHO-IBM45,46 (a stochastic
analogue of the well-established EPIONCHO transmission
model)47–49, to simulate a hypothetical phase IIb two-arm clinical
trial (i.e. a trial focused on assessing efficacy but more limited in
size than a phase III trial) comparing the efficacy of the hypo-
thetical macrofilaricide to ivermectin. The CTS can model the
(modifiable) antifilarial action of macrofilaricides and factors
defining participant eligibility. We focus on trials conducted in
previously ivermectin-naïve, mesoendemic transmission foci with
a microfilarial prevalence among individuals aged ≥ 5 years
ranging from 40% to 50% (transmission foci with higher micro-
filarial prevalence are likely to have been undergoing MDA for
many years). We compare drug responses elicited by a macro-
filaricide that is either purely macrofilaricidal (macrofilaricidal
only macrofilaricide, MOM) or that has accompanying micro-
filaricidal activity (macrofilaricidal and microfilaricidal macro-
filaricide, MAMM), and identify opportune sampling (follow-up)
times and associated sample sizes for demonstrating superiority
of these drugs (MOM and MAMM) compared to ivermectin-
treated control groups. We explore how design choices related to
participant eligibility criteria and parasitological sampling affect
the efficiency of trials and we discuss our results in the context of
the definition and refinement of TPPs, the need for improved
diagnostic indicators (biomarkers) of patent onchocerciasis, and
the implementation of trials within a landscape of MDA.
Results
Clinical trial simulation. A schematic description of the simu-
lated trial design is given in Fig. 1 and of the individual-based
onchocerciasis transmission model, EPIONCHO-IBM in Fig. 2.
An overview of the varied eligibility criteria, diagnostic protocols,
macrofilaricidal efficacies and assumed pharmacodynamics (PD)
properties of the hypothetical MOM/MAMM is given in Table 1.
Macrofilaricidal effects are modelled as the percentage of adult O.
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volvulus killed within three months of treatment. The micro-
filaricidal effect of a MAMM is assumed to be identical to that of
ivermectin (but without the temporary sterilisation or so-called
embryostatic effect, see Basáñez et al.7). Mathematical details of
EPIONCHO-IBM, including a complete description of the PD
properties of ivermectin, macrofilaricides and other adaptions
implemented to yield the CTS, are given in the Supplementary
Methods.
Treatment response dynamics. The different PD properties of
hypothetical macrofilaricides elicit profoundly different dynamics
in microfilarial outcome measures (the arithmetic mean number
of mf/mg of skin, i.e., microfilarial intensity, or the percentage of
participants positive for mf, i.e., microfilarial prevalence) with
time after treatment (Fig. 3 and Supplementary Fig. 1 for an
upper-end mesoendemic setting with a pre-treatment micro-
filarial prevalence among individuals aged ≥5 years of 50%). A
MOM elicits a slow and sustained decline in mf caused by the
decreased rate of replenishment of mf following the death of adult
worms. The rate of attrition is driven by the approximate 10-
month average life span of mf and the nadir (the lowest density of
microfilaridermia following treatment) is determined by the
competing effects of macrofilaricidal activity and reinfection by
drug-naïve worms. Incomplete clearance of adult parasites and
ongoing reinfection result in the mf population not declining to 0
and gradually repopulating (Fig. 3). The microfilaricidal activity
of a MAMM reduces the microfilarial population more rapidly,
followed by a similarly sustained suppression of mf. The more
transient effects of ivermectin arise because female worms regain
fertility and resume production of mf7, effecting a more rapid
‘bounce back’ in the parasite population. There is negligible
qualitative difference in the treatment response dynamics
between the lower and upper end of the mesoendemicity setting
(compare Fig. 3 with Supplementary Fig. 1).
Opportune follow-up timeframes. The response dynamics
define opportune follow-up timeframes for demonstrating a dif-
ference between outcome measures among macrofilaricide-
treated (test) and ivermectin-treated (control) groups. Defining
the optimal follow-up times is a balance between the average
response among participants in different groups (i.e., when the
difference between the means is greatest, Fig. 4 and Supplemen-
tary Fig. 2 for an upper-end mesoendemic setting) and the
variability in responses among participants within the same group
(i.e., when the estimated difference between means is suitably
precise, Fig. 4). For example, the greatest difference in the average
microfilarial intensity between treated (with either MOM or
MAMM) and control groups occurs between 30 and 36 months
after treatment. However, the uncertainty associated with this
difference is also greatest at these long follow-up times (Fig. 4a,
b). At follow-up times less than 12 months after treatment,
ivermectin is observed to be either superior or equally efficacious
as the macrofilaricides (MOM/MAMM) because of its rapid
microfilaricidal activity (and concomitant embryostatic effect).
The MOM begins to elicit a superior response compared to
ivermectin between 12 and 24 months after treatment (depending
on the macrofilaricidal efficacy, Fig. 4a, c). The MAMM yields
superior reductions in mf compared to ivermectin sooner,
between 6 and 12 months (depending on macrofilaricidal effi-
cacy), because of its accompanying microfilaricidal activity
Community
Individuals screened for eligibility
Microfilarial prevalence in individuals aged 5+
≈ 40% – 50%
Mesoendemic
Randomization
Ivermectin-treated
control cohort
Treatment response dynamics
(presence or absence or
mf/mg skin)
Time Time
Macrofilaricide-
treated test cohort
≥18 years old
Not pregnant or breastfeeding
Microfilarial intensity >0, >4 or >8 mf/mg
measured by 2 or 4 skin snips
Fig. 1 Schematic representation of the simulated trial design. The simulated trial is conducted in a community previously ivermectin-naïve residing in a
lower-end mesoendemic setting with a microfilarial prevalence among individuals aged ≥5 years of 40% to 50%. It is assumed that all individuals are
screened for eligibility to participate based on their age (≥18 years), their pregnancy and breastfeeding status, and their infection status (presence/absence
of microfilariae, mf) and microfilarial load (mf/mg) in the skin based on taking 2 or 4 skin snips. The presence and intensity (density) of mf in the skin, age,
sex, and pregnancy and breastfeeding status of each individual are modelled using an adapted version of EPIONCHO-IBM, along with individuals’
parasitological response to treatment with ivermectin or a hypothetical macrofilaricide that is macrofilaricidal only (MOM) or both macrofilaricidal and
microfilaricidal (MAMM).
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(Fig. 4b, d). Inference on opportune follow-up timeframes is
qualitatively very similar between the lower and upper end of the
mesoendemicity setting, albeit there is noticeably greater varia-
tion in the difference between the microfilarial intensity outcome
measure at the upper endemicity end of the setting (compare
Supplementary Fig. S2a, b with Fig. 4a, b).
Estimated sample sizes. The sample size required to achieve a
given statistical power to detect a difference between (ivermectin-
treated) control and (macrofilaricide-treated) test groups will
depend on the difference in the average response between groups
(effect size), the variability associated with this difference and on
the chosen outcome measure (microfilarial intensity or pre-
valence). For each outcome measure, effect size and variability
depend on the PD properties of the macrofilaricide (MOM/
MAMM), the follow-up timeframe and the macrofilaricidal effi-
cacy (Fig. 4). The CTS approach permits exploration of how
decisions on minimum infection inclusion criterion and the
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Fig. 2 Schematic description of EPIONCHO-IBM. EPIONCHO-IBM is an individual-based analogue of the population-based (deterministic) EPIONCHO
transmission model47, 49 tracking the number and age (a) of adult non-fertile (WFN(i,a)) and fertile (WFF(i,a)) female Onchocerca volvulus worms, microfilariae
(Mi(a)) and male worms (not represented schematically) within individual (human) hosts (i) and the mean number of L1, L2 and L3 larvae in blackfly
vectors (a). Host births, deaths and age are based on the typical demography of rural low-income communities in Africa (b) and we additionally model
explicitly the pregnancy and breastfeeding status of women between the ages of 16 and 40 years (shaded dark red (b)). Individuals are differentially
exposed to blackfly bites, driving the typically overdispersed (aggregated) distribution of parasites among hosts, such that most people are either uninfected
or lightly infected and few have many adult parasites (and microfilariae) (c). Exposure to blackfly bites depends on age and varies between boys and girls/
men and women, and is implicitly related to the amount of time spent in areas of high blackfly (vector) density. In this parameterisation, based on data from
an onchocerciasis focus in northern Cameroon, girls are relatively less exposed than boys and women are relatively more exposed than men (d)78.
The parasite population is regulated by density-dependent processes operating within the blackfly vector, and on the establishment of incoming worms and
the mating of (female) adult worms with the human host. Female worms in a host are assumed to produce microfilariae if at least one male worm is present
(i.e., polygamous mating).
Table 1 Parameters varied in the clinical trial simulation.
Parameter Values
Endemicity 40% or 50% microfilarial prevalence among individuals aged ≥5 years
Inclusion criteria >0, >4 or >8 microfilariae /mg skin
Diagnostic protocol 2 or 4 skin snips per participant
Macrofilaricidal efficacya 60%, 75% or 90%
Pharmacodynamics (PD) profile Macrofilaricidal-only macrofilaricide (MOM) or macrofilaricidal & microfilaricidalb macrofilaricide (MAMM)
aMacrofilaricidal efficacy is defined as the probability (expressed as a percentage) that an adult Onchocerca volvulus worm is killed within three months of (single dose) treatment with the
hypothetical drug.
bMicrofilaricidal effect is assumed to be identical to that of ivermectin (excluding the temporary sterilisation or so-called embryostatic effect, see Supplementary Methods).
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number of skin snips used to detect mf (Table 1 and Fig. 1) also
influence the required sample size. For examples of trials
employing different design decisions see Awadzi et al.50, Batsa
Debrah et al.51, Opoku et al.52, and Turner et al.53.
Estimated sample sizes required to detect with 80% power a
statistically significant superior response (using either microfilar-
ial intensity and prevalence) in the macrofilaricide-treated test
group compared to the ivermectin-treated control group at
various times after treatment, macrofilaricidal efficacies, inclusion
criteria and number of skin snips are shown in Fig. 5. Sample
sizes decrease with increasing macrofilaricidal efficacy, and
marginally for microfilarial intensity (because of the increased
measurement precision) for 4 versus 2 skin snips. More
pronounced effects result from the choice of outcome measure
and infection level inclusion criteria. Sample sizes are generally
lower when using microfilarial prevalence compared to micro-
filarial intensity for an inclusion criterion of >0 mf/mg because of
the lower inter-participant variability associated with the former.
However, for an increasing minimum microfilarial intensity
inclusion criterion (ranging from >0 mf/mg to >8 mf/mg)
opposing directional effects on sample sizes for the different
outcome measures are evident. For microfilarial intensity,
increasing the infection level inclusion criterion decreases
required sample sizes because inter-participant variability in
microfilarial counts is reduced (by selecting individuals with
somewhat more similar microfilarial loads). By contrast, for
microfilarial prevalence, increasing the infection level inclusion
criterion increases the sample size. This is because the selection of
more heavily infected participants decreases the number of
participants who are ostensibly ‘cured’ (i.e., achieving zero mf)
following treatment (note that macrofilaricidal efficacy is defined
probabilistically as the chance that an adult Onchocerca volvulus
worm is killed by treatment). These contrasting effects are
enhanced in the upper-end mesoendemic setting because partici-
pants tend to be more heavily infected (Supplementary Fig. 3).
Discussion
We have illustrated, using onchocerciasis as an example, how a
CTS can be used to inform the design of antifilarial drug trials by
projecting responses in outcomes measured in test and control
groups (cohorts) receiving either a (hypothetical) macrofilaricidal
treatment or an existing (predominantly microfilaricidal) com-
parator therapy. The transmission model that underpins the CTS
accounts for the inevitable reinfection of participants by drug-
naïve parasites in endemic settings. Crucially, this permits a priori
identification of opportune follow-up times after treatment when
the balance between measurable drug effects and reinfection is
most favourable. Moreover, the individual-based structure of the
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Fig. 3 Parasitological response dynamics in ivermectin-treated and macrofilaricide-treated participants. Each panel depicts the parasitological response
dynamics in two 50-participant cohorts treated with either ivermectin (purple lines) or a hypothetical macrofilaricide (red lines) in an ivermectin-naïve
lower-end mesoendemic setting. The macrofilaricide has an efficacy of 90% (90% of adult Onchocerca volvulus are killed within three months of treatment)
and either macrofilaricidal activity only (MOM, left-hand side (a, c)) or macrofilaricidal and microfilaricidal activity (MAMM, right-hand side (b, d)). The
parasitological outcome measure is either the arithmetic mean number of microfilariae (mf) per mg of skin (microfilarial intensity (a, b)) or the percentage
of participants positive for mf (microfilarial prevalence (c, d)), both measured by 2 skin snips. Participants were included in the cohort if they were positive
for mf (i.e., inclusion criterion was >0 mf/mg of skin). Each thin line represents a single simulation and the vertical error bars indicate the range which
captures 95% of the simulations. The grey lines indicate the mean (either mf per mg of skin, i.e., intensity, or presence of mf, i.e., prevalence) in the whole
population, which is assumed to comprise 1000 individuals. Note that only eligible participants are treated, i.e., (community-wide) mass drug
administration is not simulated.
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transmission model permits explicit simulation (and exploration)
of other proposed protocols, such as the use of minimum infec-
tion level eligibility criteria and sampling procedures (e.g., para-
sitological sampling by skin snips). Explicit simulation of
transmission and trial protocols represent the key benefits of
using a CTS to inform trial design.
For the PD properties of macrofilaricides (MOM/MAMM)
considered here, the best follow-up times (requiring the smallest
sample sizes) occur at least (but often greater than) 12 and
18 months after treatment. But follow-up times and required
sample sizes are also strongly influenced by the presumed efficacy
of the treatment, such that for the lowest 60% efficacy considered
here, follow-up times and/or required sample sizes may be deemed
too long to be feasible. Hence, the CTS plays an important role in
evaluating and revising a TPP as being demonstrable within a
clinical trial framework. The CTS also permits the impact of other
frequently considered trial design choices—such as pre-selection of
individuals with a minimum intensity of infection6,40, protocols to
increase diagnostic sensitivity (i.e., 4 versus 2 skins snips)54 and the
choice of primary outcome measure (i.e., prevalence versus
intensity)—to be evaluated in practically relevant quantities such as
required sample sizes.
Long follow-up times of 1 year to 18 months are a feature of
antifilarial drug trials (not necessarily including macrofilaricidal
therapies) because of the protracted and often non-curative
parasitological response to treatment53,55–57. Trials of MOMs
compared to predominantly microfilaricidal drugs incur parti-
cularly protracted follow-up times because of the indirect nature
of parasitological outcome assessment; mf populations decrease
by natural attrition after the removal of reproductively active
female worms45. This is also a feature of microfilarial responses in
clinical trials of anti-Wolbachia drugs that deplete the endo-
symbionts of O. volvulus and lymphatic filariae causing female
worm sterility and eventual death58,59. The heavy reliance on mf
as a primary outcome measure is because they are the most
accessible parasite stage and, in onchocerciasis, because there is
not any other reliable indicator of patent infection (e.g. ultra-
sound examination of onchocercomata for signs of adult worm
viability)60. Serology61 is not suitable as it predominately tests for
past exposure to O. volvulus antigens62. This is unlike LF, for
which (in addition to ultrasonography)63 there exist circulating
filarial antigen (CFA) tests64,65 which can be used as alternatives
to sampling mf66,67 and offer a more direct means of detecting
macrofilariae.
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Fig. 4 Difference in parasitological outcomes between ivermectin-treated and macrofilaricide-treated participants. Each panel depicts differences in
parasitological outcome measures between two 50-participant cohorts treated with either ivermectin (control group) or a hypothetical macrofilaricide (test
group) in an ivermectin-naïve lower-end mesoendemic setting. The macrofilaricide has an assumed efficacy of either 60% (cream points and lines), 75%
(light orange points and lines) or 90% (red points and lines). Efficacy refers to the percentage of adult Onchocerca volvulus killed within three months of
treatment. Left-hand side panels (a) and (c) show results for a macrofilaricidal only macrofilaricide (MOM); right-hand side panels (b) and (d) show
results for a macrofilaricidal and microfilaricidal macrofilaricide (MAMM). The parasitological outcome measures compared are either the difference in
arithmetic mean number of microfilariae (mf) per mg of skin (microfilarial intensity, panels (a) and (b)) or the difference in percentage of participants
positive for mf (microfilarial prevalence, panels (c) and (d)), both measured by 2 skin snips. Participants were included in the cohort if they were positive
for mf (i.e., infection status inclusion criterion was >0 mf/mg of skin). Points indicate the arithmetic mean of the simulated differences in the average
response between treatment groups and vertical error bars indicate the range which captures 95% of the differences. The horizontal dashed line indicates
the threshold of equivalence (i.e., difference = 0), above or below which the MOM/MAMM or ivermectin exhibit superiority, respectively.
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It is possible to make direct observations on the fertility and
viability of adult O. volvulus extracted from superficial (palpable
and accessible) onchocercomas (nodules) (see for example Gar-
don et al.)68. For directly acting macrofilaricides, this could be
used to assess efficacy earlier than is apparent in microfilarial
outcome measures. It also permits better understanding of drug
activity against adult filariae. Direct assessment of adult worms
collected by nodulectomy has been used extensively to demon-
strate the efficacy of anti-Wolbachia therapies in depleting
endosymbiotic Wolbachia58,69, albeit the indirect killing effect of
these therapies means that, even by this approach, detecting
macrofilaricidal activity still requires follow-up times in excess of
18 months59. However, although these methods are useful as
secondary outcome measures, it remains difficult to design and
power trials using adult worms as the primary outcome measure.
Infection with adult worms is typically diagnosed by identifying
palpable nodules but the relationship between the presence of
nodules and numbers of adult worms is highly uncertain70, and
there do not exist validated statistical models that describe the
number of adult worms typically found in onchocercomata (but
see Duerr et al.)71. Ideally, an O. volvulus antigen test would
become available to replace the invasive procedures of nodu-
lectomy or skin snipping72.
The variability in estimated sample sizes required to detect
superiority of a macrofilaricide compared to ivermectin reflects
the potential resource-saving benefits and efficiency gains that
clinical trial simulation can offer. For example, even to demon-
strate superiority of a macrofilaricide with a high 90% target
efficacy, estimates range from ≤25 to >250 participants per
cohort depending on the chosen outcome measure (microfilarial
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Fig. 5 Sample sizes required to detect a superior response in macrofilaricide-treated compared to ivermectin-treated participants. Each panel depicts
sample sizes (n) required to detect, with 80% power, a statistically significant superior response in the macrofilaricide-treated test group compared to the
ivermectin-treated control group in an ivermectin-naïve lower-end mesoendemic setting. Sample sizes are calculated at 6, 12, 18 and 24 months after
treatment assuming a 10% loss to follow up per year. Macrofilaricidal efficacy (either 60%, 75% or 90%) corresponds to the percentage of adult
Onchocerca volvulus killed within three months of treatment with a macrofilaricidal only macrofilaricide (MOM, left-hand side; panels (a) and (c)) or a
macrofilaricidal and microfilaricidal macrofilaricide (MAMM, right-hand side; panels (b) and (d)). The parasitological outcome measures are the arithmetic
mean number of microfilariae (mf) per mg of skin (microfilarial intensity, panels (a) and (b)) and the percentage of participants positive for mf
(microfilarial positive, panels (c) and (d)), both measured by 2 or 4 skin snips and using an infection eligibility criterion before treatment of either >0 (i.e.,
presence of mf), >4 or >8 mf/mg of skin. Empty squares correspond to time points when the response in the macrofilaricidal-treated test group is inferior
to ivermectin.
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intensity or prevalence), the follow-up time and the inclusion
criterion for minimum infection level. For drugs with the lowest
assumed macrofilaricidal efficacy of 60%, the trial design can
make the difference between being able or unable to demonstrate
superiority compared to ivermectin (i.e., to make the go/no go
decisions). For example, our results suggest that it is not possible
to demonstrate superiority of a MOM with 60% efficacy with a
follow up shorter than an 18-month and even at long (18- to 24-
month) follow ups, the required sample sizes will exceed 250 per
treatment group). It is a noteworthy limitation that in this CTS,
variation among drug responses is driven only by stochastic
variation in numbers of adult worms and numbers (or presence)
of mf detected by 2 or 4 skins snips (see Supplementary Meth-
ods). No consideration is given to inter-participant variation in
treatment responses73 (PD variation) which would inflate
sample sizes.
The comparatively large required sample sizes and long follow-
up times for the hypothetical MOM represents a general chal-
lenge to the evaluation of novel or repositioned antifilarial drugs
within a clinical trial structure. It is conceivable that sustained
suppression of mf elicited by drugs with even only moderate
(60%) macrofilaricidal activity is at least as beneficial to patients
than the rapid but transient clearance of mf elicited by many
microfilaricides (e.g. ivermectin and DEC). To demonstrate this
with clinical outcome measures (such as the prevalence of prur-
itus or troublesome itch, other skin pathologies and ocular
pathologies) that typically lag behind parasitological indicators of
infection74, would require prohibitively long follow-up periods
that would be difficult to justify ethically when the de facto
standard of treatment for people living in endemic areas is annual
MDA. Indeed, on this basis, proposed trials with follow-up times
greater than 12 months may face ethical challenges and require
that ivermectin (for onchocerciasis) or ivermectin with albenda-
zole or DEC (for LF) be offered to participants 1 year after
treatment or as ‘rescue’ medication if infection is detected.
A seemingly natural solution to this problem is to design trials
that concomitantly deliver the standard annual antifilarial therapy
and compare outcomes in groups treated (not necessarily at the
same time) with a macrofilaricide and a standard MDA treatment
or treated with standard MDA alone. This type of strategy has
been used in trials of anti-Wolbachia therapies for onchocerciasis
and LF which elicit a similarly protracted decline in mf (caused by
female worm sterilisation and eventual death following depletion
of endosymbiotic Wolbachia), when used as monotherapy53, to
the hypothetical MOM considered here, but which effect lasting
suppression and lower rates of microfilarial repopulation after
subsequent rounds of ivermectin treatment. Whether a MOM
would be given at the same time as ivermectin, or with sufficient
time before or after MDA rounds, would depend on the safety of
co-administration and on whether or not it would be desirable to
have a MOM registered exclusively as a component of a combi-
nation therapy with ivermectin.
Trials combining a MOM and ivermectin (whether or not as a
combination therapy), however, may be challenging in areas co-
endemic with the filarial parasite Loa loa because the killing of L.
loa mf by microfilaricides in heavily microfilaraemic individuals
can lead to severe and sometimes fatal severe adverse events
(SAEs)29. Indeed, the disruption to onchocerciasis and LF control
caused by SAEs in communities co-endemic with loiasis is a key
driver behind the current push to develop safe antifilarial drugs for
loiasis-infected patients32 and test-and(not)-treat strategies75. In
many such communities, individuals with high intensities of L. loa
microfilaraemia must be identified and excluded from receiving
microfilaricidal drugs (i.e., by test-and-not-treat strategies)75.
Hence, there remains a potential use case for MOM monotherapy
(assuming a MOM does not affect L. loa mf) or indeed anti-
Wolbachia therapies (that do not affect L. loa because they do not
harbour Wolbachia endosymbionts) in onchocerciasis-loiasis co-
endemic communities.
An alternative approach to earlier identification of macro-
filaricidal activity is to collect interim parasitological (micro-
filarial) data before the indicated optimal follow-up time. While
these data may not indicate superiority compared to ivermectin,
model-based interpretation of the data (for example by fitting the
CTS or related transmission dynamics models)8,59 will give an
indication of the underlying activity and efficacy of the trialled
drug. This may give important early indications to support ‘go /
no go’ decisions and/or inform refinement or adaption of the trial
design. For example, measuring mf from patients at interim time
points—before the initially-proposed most opportune follow-up
time—would permit the CTS to be fitted to the data to achieve an
early indication/estimate of macrofilaricidal activity and accom-
panying microfilaricidal activity. Decisions could then be made
on whether to continue the trial (e.g., depending on how the early
estimate of macrofilaricidal activity compares to the desired TPP)
and when the final follow up should be made (e.g., depending on
the indicated level of microfilaricidal activity). The efficiency
gains associated with such adaptive (as opposed to ‘fixed’) trial
designs is well recognised and has led to their increased use across
the clinical medicine domain76,77. Collection of interim long-
itudinal repeated measurements also confers added statistical
power to post hoc analyses and can supplement the final com-
parison of trialled treatments.
Conducting antifilarial drug trials in the current global inter-
vention landscape of onchocerciasis and LF, where many mod-
erate to high intensity endemic communities have been
undergoing MDA for many years, poses significant logistical and
inferential challenges to trial design. For example, the use of a
high minimum infection inclusion criterion will make it harder to
find sufficient numbers of eligible participants (see Supplemen-
tary Fig. 4) within single communities or transmission foci with
similar intensities of transmission (driven by local density of
vectors). Hence, if choosing microfilarial intensity as the desired
outcome measure, there is a trade-off between the benefit of
reducing variability in treatment responses (and lower sample
sizes) by selecting participants with more similar (and higher)
infection intensities and the challenge of recruiting sufficient
numbers. Moreover, in communities where awareness of onch-
ocerciasis has diminished—following years of MDA that has
effectively controlled the disease as a public health problem—the
challenges of recruiting and retaining participants during the trial
may increase.
Designing trials in communities with long histories of MDA
adds further complexity and additional uncertainty. For example,
even given at annual MDA frequencies, ivermectin exerts notable
(but uncertain) macrofilariacidal effects on O. volvulus worms
and cumulative reductions in female worm fertility8 which will
propagate into the projected response dynamics following treat-
ment. Hence, assumptions on the cumulative effect on female O.
volvulus of multiple exposures to ivermectin will likely have a
substantial effect on projected response dynamics. Moreover,
obtaining accurate and reliable information on how many prior
rounds of treatment individual participants have received is a
challenge, although information on how many rounds of MDA
have been distributed at a population level is more readily
available. Hence, even if trials cannot be conducted in treatment-
naïve communities, we suggest that efforts should be made to
select participants with as few as possible previous antifilarial
treatments.
Notwithstanding these challenges, the CTS presented here can
in principle be used to simulate trials conducted in a variety of
epidemiological settings, with different histories of MDA.
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Parameters relating to the core transmission dynamics of onch-
ocerciasis have been estimated and refined in numerous previous
studies45,47,78,79 and capture well the observed epidemiological
relationship between ABR and microfilarial prevalence and
intensity45. Consequently, the CTS can reflect transmission
conditions across the wide spectrum of endemic settings by
varying the annual biting rate (ABR) of blackfly vectors. It can
also be used, more cautiously, to simulate trials conducted in a
backdrop of MDA by varying parameters that control the num-
ber, frequency and coverage of past and ongoing mass treatments
with ivermectin45. Installation and use of the CTS and examples
of simulating trials in a variety of epidemiological contexts are
given in the README.html file at https://mrc-ide.github.io/
EPIONCHO-IBM-CTS/README.html. The README.html also
includes instructions on how to vary parameters relevant to the
trial design, such as those varied in this work (Table 1), and
additional parameters, such as the participant dropout rate
(which was here set to a nominal 10% per year).
We have illustrated how a CTS can be used to inform the
design of antifilarial drugs, using as an example a simple two-arm
(phase IIb) trial of a hypothetical macrofilaricide compared to
ivermectin for the treatment of onchocerciasis. The approach
helps to maximise the efficiency of trials, indicating opportune
follow-up times for detecting desired drug properties and aiding
decision making on TPPs, participant eligibility criteria and
sampling protocols. The CTS developed here could be extended
to simulate more complex trials, including trials with multiple
comparator arms, combinations of therapies either given con-
currently or intermittently to meet existing standards of regular
MDA-based treatment (in addition to the existing capability to
project responses to treatment in communities with past and
ongoing MDA). Because the CTS presented here is based on a full
transmission model of infection, it is readily extendable to project
the potential wider epidemiological impact of new antifilarial
drugs or combinations, an approach that has been used to sup-
port the registration of moxidectin for the treatment of oncho-
cerciasis80 and the recent recommendation by the World Health
Organization (WHO) to endorse the IDA (ivermectin, DEC and
albendazole) triple therapy for LF81. We believe that the resource-
saving payoffs of prospective trial simulation make them an
essential tool for designing drug trials in the resource-limited
context of filarial infections and other NTDs.
Methods
Model overview. We developed a CTS from the individual-based onchocerciasis
transmission model EPIONCHO-IBM45 to simulate a trial conducted in an
ivermectin-naïve mesoendemic community with a microfilarial prevalence in those
aged ≥5 years of either 40% or 50%. A full mathematical description of the model is
given in Hamley et al45. and also in the Supplementary Methods. Briefly,
EPIONCHO-IBM is an analogue of the population-based EPIONCHO model47,49
tracking the number of adult Onchocerca volvulus worms of both sexes and
microfilariae (mf) within individual (human) hosts (Fig. 2a). Host births and
deaths are based on the typical demography of rural low-income communities in
Africa (Fig. 2b) and individuals are differentially exposed to blackfly bites, driving
in a mechanistic fashion the typically overdispersed (aggregated) distribution of
parasites among hosts (Fig. 2c). Exposure to blackfly bites varies with age and
between males and females, following epidemiological patterns typically found in
West Africa78 (Fig. 2d). Sexual reproduction of O. volvulus is modelled by
assuming that only female worms in hosts concurrently infected with at least one
male worm will produce mf. The age, sex, pregnancy and breastfeeding status
(assuming that women between 16 and 40 may be pregnant or breastfeeding for 2
years; i.e., after a 9-month pregnancy and 1 year and 3 months of breastfeeding) of
each human in the population is modelled (Fig. 2b).
Participant eligibility and randomisation. We assumed that everyone aged ≥18
years in a population of 1000 individuals who were not pregnant or breastfeeding
were screened for mf (by skin snipping). We further assumed that a set (target)
number of eligible individuals consented to participate (we targeted 50 participants
per cohort for the purpose of approximating the mean and variance among
individual response dynamics to estimate sample sizes). We randomly assigned
consenting participants to receiving either a hypothetical macrofilaricidal treatment
(the ‘test’ group) or ivermectin (the ‘control’ group, Fig. 1). The design most closely
mirrors a phase IIb trial that is focused on comparing the efficacy of a new drug (a
macrofilaricide) with an existing one (ivermectin) but is more limited in size than a
typical phase III trial (see for examples the phase II and III trials of moxidectin for
the treatment of onchocerciasis)50,52.
Pharmacodynamics assumptions. The hypothetical macrofilaricides were
assumed to be either purely macrofilaricidal, with no effect on mf, or macro-
filaricidal and microfilaricidal. These are referred to, respectively, as
macrofilaricidal-only macrofilaricides (MOMs) or macrofilaricidal and micro-
filaricidal macrofilaricides (MAMMs). Macrofilaricides were assumed to kill a
fraction of adult worms over three months that was varied between 60% and 90%
(Table 1). The MAMMs were assumed to have microfilaricidal effects identical to
the microfilaricidal dynamics (but excluding the temporary sterilising or
embryostatic effect) of ivermectin, i.e., rapid depletion of mf by 98–99% after
1–2 months7.
Simulated response dynamics. Parasitological (mf) responses to ivermectin and
hypothetical macrofilaricides in individual participants were simulated for
36 months after treatment. We incorporated a statistical model for the sampling of
mf by skin snipping, assuming an aggregated distribution of mf within the skin to
capture the relatively poor sensitivity of skin snipping, particularly at low inten-
sities of (adult worm) infection54. The infection status (positive or negative by skin
snip, >0 mf/mg skin) or intensity (>4 or >8 mf/mg skin) that defined eligibility as
measured by taking 2 or 4 skin snips was varied (Table 1).
We repeated 1,000 simulations, with each simulation targeting recruitment of
two 50-participant cohorts (note that for an increasing minimum infection
intensity inclusion criterion, the chance of recruiting 50 eligible participants
decreases, see Supplementary Fig. 4), for each parameter combination indicated in
Table 1 (72 parameter combinations; 72,000 simulations). For each simulation, we
calculated the mean difference between outcome measures (i.e., mean number of
mf/mg of skin per participant or mean percentage of participants positive for mf)
in the (macrofilaricide-treated), test, and (ivermectin-treated), control groups at
time τ, D^ τð Þ (i.e., the mean response in the control group subtracted from the
mean response in the test group, e.g., Fig. 4), and the standard deviation within
each group, σ^T τð Þ and σ^C τð Þ (T= test, C= control).
Sample size estimation. From the estimates of D^ τð Þ, σ^T τð Þ and σ^C τð Þ (one esti-
mate per simulation) we calculated Welch’s t-statistic and the expected ‘true’ value
of each parameter, D τð Þ, σT τð Þ and σC τð Þ to approximate the non-centrality and
degrees of freedom parameters for the non-central t-distribution (assuming
unequal variances). We confirmed that these (non-centrality; degrees of freedom)
parameters approximated adequately the simulated distributions of Welch’s t-
statistic (Supplementary Figs. 5–7) and proceeded to estimate sample sizes (to the
nearest 25) required to achieve an 80% probability (power) of detecting a superior
response (positive difference) in macrofilaricide-treated, test participants compared
to ivermectin-treated controls, assuming a type I error (false rejection of the null
hypothesis of no positive difference) of 5% and 10% drop out per year of recruited
participants.
Our approach to estimating sample sizes assumes that the simulated target of 50
participants per cohort provide an adequate approximation to the ‘true’ average
response and that these quantities (mean and inter-participant variance) are
consistent across changing sample sizes. In essence, this assumption rests on the
trial itself having limited immediate impact on community-wide transmission (and
therefore rates of reinfection). Sample sizes are thus interpreted qualitatively in
terms of the directional (increasing/decreasing) influence of changing design-
relevant parameter values. Further details on the sample size estimation approach
are given in Supplementary Methods.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
No external data were used. The individual-level simulated data generated during this
study are available from the corresponding author on reasonable request.
Code availability
The model code is freely available at https://github.com/mrc-ide/EPIONCHO-IBM-CTS.
Instructions for installing and running the model in R (version 3.6.2) are available in the
README.html file which can be accessed at https://mrc-ide.github.io/EPIONCHO-
IBM-CTS/README.html.
Received: 3 May 2019; Accepted: 3 May 2020;
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16442-y ARTICLE
NATURE COMMUNICATIONS | (2020)11:2685 | https://doi.org/10.1038/s41467-020-16442-y | www.nature.com/naturecommunications 9
References
1. African Programme for Onchocerciasis Control. Eighteenth Session of the Joint
Action Forum, http://www.who.int/apoc/about/structure/jaf/
Final_Communique_JAF_18_English_final_with_annexes.pdf (2012).
2. World Health Organization. Accelerating work to overcome the global impact
of neglected tropical 13. diseases – a roadmap for implementation executive
summary (World Health Organization, Geneva, Switzerland, 2012).
3. Pion, S. D. S. et al. Effect of 3 years of biannual mass drug administration with
albendazole on lymphatic filariasis and soil-transmitted helminth infections: a
community-based study in Republic of the Congo. Lancet Infect. Dis. 17,
763–769 (2017).
4. King, C. L. et al. A trial of a triple-drug treatment for lymphatic filariasis. N.
Engl. J. Med. 379, 1801–1810 (2018).
5. World Health Organization. Progress report on the elimination of human
onchocerciasis, 2017-2018. Wkly. Epidemiol. Rec. 47, 633–648 (2018).
6. World Health Organization. Global programme to eliminate lymphatic
filariasis: progress report, 2017. Wkly. Epidemiol. Rec. 93, 589–604 (2018).
7. Basáñez, M. G. et al. Effect of single-dose ivermectin on Onchocerca volvulus: a
systematic review and meta-analysis. Lancet Infect. Dis. 8, 310–322 (2008).
8. Walker, M. et al. Macrofilaricidal efficacy of repeated doses of ivermectin for
the treatment of river blindness. Clin. Infect. Dis., https://doi.org/10.1093/cid/
cix616 (2017).
9. Bockarie, M. J. et al. Efficacy of single-dose diethylcarbamazine compared with
diethylcarbamazine combined with albendazole against Wuchereria bancrofti
infection in Papua New Guinea. Am. J. Trop. Med. Hyg. 76, 62–66 (2007).
10. Ichimori, K. et al. Global programme to eliminate lymphatic filariasis: the
processes underlying programme success. PLoS Negl. Trop. Dis. 8, e3328
(2014).
11. Irvine, M. A. et al. Modelling strategies to break transmission of lymphatic
filariasis-aggregation, adherence and vector competence greatly alter
elimination. Parasite Vector 8, 547 (2015).
12. Turner, H. C., Walker, M., Churcher, T. S. & Basáñez, M. G. Modelling the
impact of ivermectin on river blindness and its burden of morbidity and
mortality in African Savannah: EpiOncho projections. Parasite Vector 7, 241
(2014).
13. Coffeng, L. E. et al. African Programme For Onchocerciasis Control 1995-
2015: model-estimated health impact and cost. PLoS Negl. Trop. Dis. 7, e2032
(2013).
14. West, S., Munoz, B. & Sommer, A. River blindness eliminated in Colombia.
Ophthalmic Epidemiol. 20, 258–259 (2013).
15. Lovato, R. et al. Interruption of infection transmission in the onchocerciasis
focus of Ecuador leading to the cessation of ivermectin distribution. PLoS
Negl. Trop. Dis. 8, e2821 (2014).
16. Convit, J. et al. Interruption of Onchocerca volvulus transmission in Northern
Venezuela. Parasite Vector 6, 289 (2013).
17. Rodríguez-Pérez, M. A. et al. Elimination of onchocerciasis from Mexico.
PLoS Negl. Trop. Dis. 9, e0003922 (2015).
18. World Health Organization. Progress towards eliminating onchocerciasis in
the WHO Region of the Americas: verification of elimination of transmission
in Guatemala. Wkly. Epidemiol. Rec. 91, 501–516 (2016).
19. Tekle, A. H. et al. Impact of long-term treatment of onchocerciasis with
ivermectin in Kaduna State, Nigeria: first evidence of the potential for
elimination in the operational area of the African Programme for
Onchocerciasis Control. Parasite Vector 5, 28 (2012).
20. Diawara, L. et al. Feasibility of onchocerciasis elimination with ivermectin
treatment in endemic foci in Africa: first evidence from studies in Mali and
Senegal. PLoS Negl. Trop. Dis. 3, e497 (2009).
21. Traoré, M. O. et al. Proof-of-principle of onchocerciasis elimination with
ivermectin treatment in endemic foci in Africa: final results of a study in Mali
and Senegal. PLoS Negl. Trop. Dis. 6, e1825 (2012).
22. Higazi, T. B. et al. Interruption of Onchocerca volvulus transmission in the
Abu Hamed focus, Sudan. Am. J. Trop. Med Hyg. 89, 51–57 (2013).
23. Verver, S. et al. How can onchocerciasis elimination in Africa be accelerated?
Modelling the impact of increased ivermectin treatment frequency and
complementary vector control. Clin. Infect. Dis. 66, S267–S274 (2018).
24. Katabarwa, M. N. et al. Fifteen years of annual mass treatment of
onchocerciasis with ivermectin have not interrupted transmission in the west
region of cameroon. J. Parasitol. Res. 2013, 420928 (2013).
25. Katabarwa, M. N. et al. Transmission of Onchocerca volvulus continues in
Nyagak-Bondo focus of northwestern Uganda after 18 years of a single dose of
annual treatment with ivermectin. Am. J. Trop. Med. Hyg. 89, 293–300 (2013).
26. Lamberton, P. H. et al. Onchocerciasis transmission in Ghana: persistence
under different control strategies and the role of the simuliid vectors. PLoS
Negl. Trop. Dis. 9, e0003688(2015).
27. Wanji, S. et al. Situation analysis of parasitological and entomological indices
of onchocerciasis transmission in three drainage basins of the rain forest of
South West Cameroon after a decade of ivermectin treatment. Parasite Vector
8, 202 (2015).
28. Zouré, H. G. et al. The geographic distribution of Loa loa in Africa: results of
large-scale implementation of the Rapid Assessment Procedure for Loiasis
(RAPLOA). PLoS Negl. Trop. Dis. 5, e1210 (2011).
29. Gardon, J. et al. Serious reactions after mass treatment of onchocerciasis
with ivermectin in an area endemic for Loa loa infection. Lancet 350, 18–22
(1997).
30. Frempong, K. K. et al. Does increasing treatment frequency address
suboptimal responses to ivermectin for the control and elimination of river
blindness? Clin. Infect. Dis. 62, 1338–1347 (2016).
31. Doyle, S. R. et al. Genome-wide analysis of ivermectin response by Onchocerca
volvulus reveals that genetic drift and soft selective sweeps contribute to loss of
drug sensitivity. PLoS Negl. Trop. Dis. 11, e0005816 (2017).
32. Kuesel, A. C. Research for new drugs for elimination of onchocerciasis in
Africa. Int J. Parasitol. Drugs Drug Resist. 6, 272–286 (2016).
33. Hopkins, A. D. Ivermectin and onchocerciasis: is it all solved? Eye (Lond.) 19,
1057–1066 (2005).
34. Alley, W. S. et al. Macrofilaricides and onchocerciasis control, mathematical
modelling of the prospects for elimination. BMC Public Health 1, 12 (2001).
35. World Health Organization Consultative Expert Working Group (CEWG) on
Research & Development. Financing & incentives for neglected disease R&D:
Opportunities and challenges (Drug for Neglected Diseases intiative, Geneva,
2011).
36. Dimitri, N. R&D incentives for neglected diseases. PLoS ONE 7, e50835
(2012).
37. Taylor, M. J., Hoerauf, A., Townson, S., Slatko, B. E. & Ward, S. A. Anti-
Wolbachia drug discovery and development: safe macrofilaricides for
onchocerciasis and lymphatic filariasis. Parasitology 141, 119–127 (2014).
38. Drugs for Neglected Diseases initiative. An innovative approach to R&D for
nelgected patients: tends years of experience and lessions learned by DNDi,
https://www.dndi.org/wp-content/uploads/2009/03/DNDi_Modelpaper_2013.
pdf (2013).
39. Holford, N., Ma, S. C. & Ploeger, B. A. Clinical trial simulation: a review. Clin.
Pharm. Ther. 88, 166–182 (2010).
40. Vegvari, C. et al. Using clinical trial simulators to analyse the sources of
variance in clinical trials of novel therapies for acute viral infections. PLoS
ONE 11, e0156622 (2016).
41. Kimko, H. & Pinheiro, J. Model-based clinical drug development in the
past, present and future: a commentary. Br. J. Clin. Pharm. 79, 108–116
(2015).
42. Hollingsworth, T. D. et al. Quantitative analyses and modelling to support
achievement of the 2020 goals for nine neglected tropical diseases. Parasite
Vector 8, 630 (2015).
43. Anderson, R. et al. Assessing the interruption of the transmission of human
helminths with mass drug administration alone: optimizing the design of
cluster randomized trials. Parasite Vector 10, 93 (2017).
44. Truscott, J. E. et al. Identifying optimal threshold statistics for elimination of
hookworm using a stochastic simulation model. Parasite Vector 10, 321 (2017).
45. Hamley, J. I., Milton, P., Walker, M. & Basa  ñez, M.-G. Modelling exposure
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